Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (248 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 04 Aug 2022 – 20 Aug 2026, limited by Motilal Oswal BSE Healthcare ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Motilal Oswal BSE Healthcare ETF | Nifty 500 |
|---|---|---|
| 04 Aug 2022 | ₹100.00 | ₹100.00 |
| 05 Dec 2022 | ₹102.57 | ₹107.22 |
| 07 Apr 2023 | ₹95.85 | ₹99.11 |
| 08 Aug 2023 | ₹122.56 | ₹113.81 |
| 09 Dec 2023 | ₹131.27 | ₹125.59 |
| 10 Apr 2024 | ₹154.57 | ₹140.44 |
| 12 Aug 2024 | ₹178.05 | ₹153.88 |
| 13 Dec 2024 | ₹191.00 | ₹156.85 |
| 15 Apr 2025 | ₹179.13 | ₹142.89 |
| 16 Aug 2025 | ₹193.42 | ₹152.29 |
| 17 Dec 2025 | ₹189.40 | ₹157.77 |
| 19 Apr 2026 | ₹189.32 | ₹153.56 |
| 20 Aug 2026 | ₹221.37 | ₹157.89 |
| Metric | Motilal Oswal NAV ₹51.48 Very High risk ★★★★★ | Category median Other ETFs · 248 funds |
|---|---|---|
| +14.33% | +3.65% | |
| +22.48% | +10.51% | |
| — | +9.28% | |
| — | +11.93% | |
| +21.71% | +10.38% | |
| +21.65% | — | |
| +24.62% | +14.30% | |
| — | +13.74% | |
| — | +12.83% | |
| Risk | ||
| 14.06% | 15.45% | |
| 1.14 | 0.28 | |
| 1.61 | 0.41 | |
| -16.15% | -20.59% | |
| Nifty 500 | — | |
| +10.77% | +0.80% | |
| 0.78 | 1.00 | |
| 117.0% | 102.1% | |
| 66.1% | 96.4% | |
| 0.39% | 0.32% | |
| ₹41.40Cr | ₹137.31Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| Rakesh Shetty | — | |
| 04 Aug 2022 | — | |
| 125 | — | |
| 55.4% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.